SEC Company Response from ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510) (VISK) — Jan 8, 2009
ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)
Date: Jan. 8, 2009 · CIK: 0000727510 · Accession: 0000930413-09-000135
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-12957
Letter
United States Securities and Exchange Commission Enzon Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2007 Filed February 29, 2008 File Number: 000-12957
Dear Mr. Rosenberg:
By telephonic communication from the Staff of the Commission, the Staff provided a comment regarding the Form 10-K for the Fiscal Year Ended December 31, 2007 (the “Form 10-K”) of Enzon Pharmaceuticals, Inc. (the “Company”) filed February 29, 2008. Enclosed please find the response to this comment.
1.
Please refer to your response to comment # 3. Please revise your disclosure to clarify that the Company does not have any continuing involvement in the selling or marketing of PEG-Intron and has no impact over the future royalty stream of PEG-Intron. Please clarify that the payment was non-refundable and that the amount received is a fixed amount but is not dependant on the future royalty stream.
Response:
The Company confirms that it has no continuing involvement in the selling or marketing of PEG-Intron, has no impact over the future royalty stream of PEG-Intron, that the upfront payment of $92.5 million received was non-refundable, was fixed in amount and is not dependent on the future royalty stream of PEG-Intron. As requested by the Staff, the Company will include this additional disclosure in the 10-K filing for the year ended December 31, 2008.
We acknowledge that:
The Company is responsible for the adequacy and accuracy of the disclosure in the filing;
Staff comments or changes to disclosures in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If I can be of any further assistance, please do not hesitate to contact me at (908) 541-8759.
Very truly yours,
/s/ Craig A. Tooman
Show Raw Text
CORRESP
1
filename1.htm
c56266_corresp.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing
January 8, 2009
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
United States
Securities and Exchange Commission
Washington, D.C. 20549
Mail Stop 6010
RE:
Enzon Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2007
Filed February 29, 2008
File Number: 000-12957
Dear Mr. Rosenberg:
By telephonic communication from the Staff of the Commission, the Staff provided a comment regarding the Form 10-K for the Fiscal Year Ended December 31, 2007 (the “Form 10-K”) of Enzon Pharmaceuticals, Inc. (the
“Company”) filed February 29, 2008. Enclosed please find the response to this comment.
1.
Please refer to your response to comment # 3. Please revise your disclosure to clarify that the Company does not have any continuing involvement in the selling or marketing of PEG-Intron and has no impact over the future
royalty stream of PEG-Intron. Please clarify that the payment was non-refundable and that the amount received is a fixed amount but is not dependant on the future royalty stream.
Response:
The Company confirms that it has no continuing involvement in the selling or marketing of PEG-Intron, has no impact over the future royalty stream of PEG-Intron, that the upfront payment of $92.5 million received was
non-refundable, was fixed in amount and is not dependent on the future royalty stream of PEG-Intron. As requested by the Staff, the Company will include this additional disclosure in the 10-K filing for the year ended December 31, 2008.
We acknowledge that:
The Company is responsible for the adequacy and accuracy of the disclosure in the filing;
Staff comments or changes to disclosures in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United
States.
If I can be of any further assistance, please do not hesitate to contact me at (908) 541-8759.
Very truly yours,
/s/ Craig A. Tooman
Craig A. Tooman
EVP Finance and CFO